TipRanks
Advertisement
Advertisement
Analyst Raises Adaptive’s Price Target to $34 on Strengthening clonoSEQ MRD Adoption and NCCN Guideline Support
PremiumRatingsAnalyst Raises Adaptive’s Price Target to $34 on Strengthening clonoSEQ MRD Adoption and NCCN Guideline Support
14d ago
Adaptive Biotechnologies reports update to NCCN guidelines for Multiple Myeloma
Premium
The Fly
Adaptive Biotechnologies reports update to NCCN guidelines for Multiple Myeloma
19d ago
Adaptive Biotechnologies price target raised to $27.50 from $20 at Piper Sandler
Premium
The Fly
Adaptive Biotechnologies price target raised to $27.50 from $20 at Piper Sandler
2M ago
Adaptive Biotechnologies price target raised to $25 from $22 at Guggenheim
PremiumThe FlyAdaptive Biotechnologies price target raised to $25 from $22 at Guggenheim
2M ago
Analyst Reaffirms Buy on Adaptive Biotechnologies, Lifting Price Target to $25 Amid Strong MRD Momentum and Raised 2026 Guidance
Premium
Ratings
Analyst Reaffirms Buy on Adaptive Biotechnologies, Lifting Price Target to $25 Amid Strong MRD Momentum and Raised 2026 Guidance
2M ago
Adaptive Biotechnologies Earns Buy Rating as Strong MRD-Driven Revenue Beat and Margin Expansion Support Attractive Risk-Reward
Premium
Ratings
Adaptive Biotechnologies Earns Buy Rating as Strong MRD-Driven Revenue Beat and Margin Expansion Support Attractive Risk-Reward
2M ago
Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley
PremiumThe FlyAdaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley
3M ago
Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim
Premium
The Fly
Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim
3M ago
Adaptive Biotechnologies Issues Convertible Notes to Reshape Capital
Premium
Company Announcements
Adaptive Biotechnologies Issues Convertible Notes to Reshape Capital
4M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―